454 Checkpoint modification of early T cell activation provides enhanced anti-tumor activity and survival benefits in a fast-growing preclinical tumor challenge model

Abstract

BackgroundCheckpoint inhibitors (CPI) that target activated, impaired T cells, have revolutionized cancer treatments. However, there are limited data on CPIs that affect T cell activation. HSV-1 glycoprotein D (gD) binds...